Stocks · News reference

Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10

Jul 13, 2026, 5:59 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 25, 2026, 8:34 PMBenzinga Newsdesk
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Adjustments have no impact on cash and cash equivalents, cash runway, or business operations.Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated
NGEN
BenzingaJul 14, 2026, 12:19 PMAvi Kapoor
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday
Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See how other analysts view these stocks.
ABNB AFRM FCEL HAL JAZZ
BenzingaJul 14, 2026, 10:19 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a Buy and lowers the price target from $18 to $15.
NGEN